When.com Web Search

  1. Ads

    related to: cost effective analysis ppt slides free

Search results

  1. Results From The WOW.Com Content Network
  2. Cost-effectiveness analysis - Wikipedia

    en.wikipedia.org/wiki/Cost-effectiveness_analysis

    A complete compilation of cost-utility analyses in the peer-reviewed medical and public health literature is available from the Cost-Effectiveness Analysis Registry website. [6] A 1995 study of the cost-effectiveness of reviewed over 500 life-saving interventions found that the median cost-effectiveness was $42,000 per life-year saved. [7]

  3. Pharmacoeconomics - Wikipedia

    en.wikipedia.org/wiki/Pharmacoeconomics

    Pharmacoeconomics centers on the economic evaluation of pharmaceuticals, and can use cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis or cost-utility analysis. Quality-adjusted life years have become the dominant outcome of interest in pharmacoeconomic evaluations, and many studies employ a cost-per-QALY analysis.

  4. Incremental cost-effectiveness ratio - Wikipedia

    en.wikipedia.org/wiki/Incremental_cost...

    The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect.

  5. Techno-economic assessment - Wikipedia

    en.wikipedia.org/wiki/Techno-economic_assessment

    Techno-economic assessment or techno-economic analysis (abbreviated TEA) is a method of analyzing the economic performance of an industrial process, product, or service. The methodology originates from earlier work on combining technical, economic and risk assessments for chemical production processes. [ 1 ]

  6. Cost–utility analysis - Wikipedia

    en.wikipedia.org/wiki/Cost–utility_analysis

    Thus, any health intervention which has an incremental cost of more than £30,000 per additional QALY gained is likely to be rejected and any intervention which has an incremental cost of less than or equal to £30,000 per extra QALY gained is likely to be accepted as cost-effective. This implies a value of a full life of about £2.4 million.

  7. Amgen (AMGN) Q4 2024 Earnings Call Transcript - AOL

    www.aol.com/finance/amgen-amgn-q4-2024-earnings...

    The financial results are shown on Slide 28 to 30 of the slide deck. Full year total revenues of 33.4 billion grew 19% year over year, driven by 21 products with record sales.